Introduction Thymic epithelial tumors are a rare type of neoplasm. Accordingly, it is difficult to
perform phase III trials in patients with thymic epithelial tumors, and thus, no standard …

BACKGROUND: Thymic carcinoma is a rare malignancy with little information regarding
outcomes after therapy with curative intent. We undertook a retrospective analysis of all …

Background Total resection may not be achieved in patients with thymic carcinoma,
particularly those with Masaoka stage III disease. Debulking surgery plus postoperative …

Abstract Introduction Thymic epithelial tumors (TETs) are rare malignancies that may be
aggressive and difficult to treat. In the advanced setting, systemic treatments may be …

Objective For rarity of thymic carcinoma, no definitive chemotherapeutic regimen has been
established in second-or further-line settings. The aim of this study was to evaluate the …

Thymic carcinoma (TC) is a rare thymic epithelial neoplasm with an aggressive clinical
course. There are many recognized histologic subtypes as described by the fifth edition of …

Objectives The objectives of this collaborative study were to characterize patients with
thymic carcinoma, their treatment patterns, and association with overall survival (OS) and …

Background Thymic carcinoma (TC) is a rare tumor with aggressive behavior.
Chemotherapy with carboplatin plus paclitaxel represents the treatment of choice for …

Background This study aimed to analyze the pattern of lymphogenous and hematogenous
metastases in patients with stage IVb thymic carcinomas and identify prognostic factors for …

Background To evaluate long‐term survival in thymic epithelial tumors (TETs), we present
our experiences at a single institution in China. Methods We performed a retrospective …